Cargando…
Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120014/ https://www.ncbi.nlm.nih.gov/pubmed/24988185 http://dx.doi.org/10.1038/psp.2014.20 |
_version_ | 1782329033204170752 |
---|---|
author | Møller, J B Kristensen, N R Klim, S Karlsson, M O Ingwersen, S H Kjellsson, M C |
author_facet | Møller, J B Kristensen, N R Klim, S Karlsson, M O Ingwersen, S H Kjellsson, M C |
author_sort | Møller, J B |
collection | PubMed |
description | The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c on fasting plasma glucose and mean plasma glucose, respectively, (3) an indirect response model of fasting plasma glucose effects on HbA1c, (4) model of glycosylation of red blood cells, and (5) coupled indirect response model for mean plasma glucose and HbA1c. Absolute mean prediction errors were 0.61, 0.38, 0.55, 0.37, and 0.15% points, respectively, for Methods 1 through 5. This indicates that predictions improved by using mean plasma glucose instead of fasting plasma glucose, by inclusion of longitudinal glucose data and further by inclusion of longitudinal HbA1c data until 12 weeks. For prediction of trial outcome, the longitudinal models based on mean plasma glucose (Methods 4 and 5) had substantially better performance compared with the other methods. |
format | Online Article Text |
id | pubmed-4120014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-41200142014-08-15 Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches Møller, J B Kristensen, N R Klim, S Karlsson, M O Ingwersen, S H Kjellsson, M C CPT Pharmacometrics Syst Pharmacol Original Article The link between glucose and HbA1c at steady state has previously been described using steady-state or longitudinal relationships. We evaluated five published methods for prediction of HbA1c after 26/28 weeks using data from four clinical trials. Methods (1) and (2): steady-state regression of HbA1c on fasting plasma glucose and mean plasma glucose, respectively, (3) an indirect response model of fasting plasma glucose effects on HbA1c, (4) model of glycosylation of red blood cells, and (5) coupled indirect response model for mean plasma glucose and HbA1c. Absolute mean prediction errors were 0.61, 0.38, 0.55, 0.37, and 0.15% points, respectively, for Methods 1 through 5. This indicates that predictions improved by using mean plasma glucose instead of fasting plasma glucose, by inclusion of longitudinal glucose data and further by inclusion of longitudinal HbA1c data until 12 weeks. For prediction of trial outcome, the longitudinal models based on mean plasma glucose (Methods 4 and 5) had substantially better performance compared with the other methods. Nature Publishing Group 2014-07 2014-07-02 /pmc/articles/PMC4120014/ /pubmed/24988185 http://dx.doi.org/10.1038/psp.2014.20 Text en Copyright © 2014 American Society for Clinical Pharmacology and Therapeutics http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Møller, J B Kristensen, N R Klim, S Karlsson, M O Ingwersen, S H Kjellsson, M C Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title | Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title_full | Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title_fullStr | Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title_full_unstemmed | Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title_short | Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches |
title_sort | methods for predicting diabetes phase iii efficacy outcome from early data: superior performance obtained using longitudinal approaches |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120014/ https://www.ncbi.nlm.nih.gov/pubmed/24988185 http://dx.doi.org/10.1038/psp.2014.20 |
work_keys_str_mv | AT møllerjb methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches AT kristensennr methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches AT klims methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches AT karlssonmo methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches AT ingwersensh methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches AT kjellssonmc methodsforpredictingdiabetesphaseiiiefficacyoutcomefromearlydatasuperiorperformanceobtainedusinglongitudinalapproaches |